Condition: Hypoxic Ischemic Encephalopathy (HIE) · Sponsor: NICHD Global Network for Women's and Children's Health
CHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an umbilical cord or early \[\<1 hour\] postnatal blood sample) and neurologic criteria (modified Sarnat exam consistent with encephalopathy). Following informed consent, and by six hours after birth, neonates with HIE will be randomized to one of two treatment arms and subsequently receive one 20 mg/kg dose of oral caffeine followed by two additional 10 mg/kg doses at 24-hour intervals or placebo of the same regimen (three total doses). The goal of this clinical trial is to compare the incidence of all-cause mortality OR moderate to severe neurodevelopmental impairment (NDI) at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo. Our hypothesis is that neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.
This description comes directly from the study's public registry record.
Laura Danielle Wagner, MPH · +1-919-541-6000 · wagner@rti.org
Jennifer J Hemingway-Foday, MPH, MSW · hemingway@rti.org
Always discuss trial participation with your own doctor first.
| ICDDR,B | Saidpur, Bangladesh | Recruiting |
| Kinshasa School of Public Health | Kinshasa, Democratic Republic of the Congo | Not Yet Recruiting |
| Institute of Nutrition of Central America And Panama (INCAP) | Chimaltenango, Guatemala | Recruiting |
| KLE University's J N Medical College | Belagavi, India | Not Yet Recruiting |
| Lata Medical Research Foundation | Nagpur, India | Not Yet Recruiting |
| Aga Khan University | Karachi, Pakistan | Not Yet Recruiting |
| University Teaching Hospital | Lusaka, Zambia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06855108